Blog
RSS FeedPosted by Michael Wonder on 25 Jul 2023
Peter Mac increases manufacturing centre for gene therapy bringing new hope to cancer patients
25 July 2023 - Australia’s first biomedical manufacturing facility has opened in Melbourne and will boost lifesaving therapy for cancer patients ...
Posted by Michael Wonder on 19 Jun 2022
IP waiver for COVID vaccines is a threat to future innovation
20 June 2022 - The decision to waive intellectual property protections for COVID-19 vaccines is fundamentally flawed and will have ...
Posted by Michael Wonder on 13 Jun 2022
IP waiver for COVID vaccines misses the mark in vaccinating the world
14 June 2022 - Vaccinating the world remains a priority and proposals to weaken the intellectual property for COVID-19 vaccines ...
Posted by Michael Wonder on 14 Dec 2021
mRNA manufacturing facility will deliver long term health benefits for Australians
14 December 2021 - Medicines Australia welcomes the announcement that Australia will manufacture mRNA vaccines in a deal struck with ...
Posted by Michael Wonder on 05 Oct 2021
Pharmaceutical industry backs workplace vaccinations
5 October 2021 - Medicines Australia strongly recommends full COVID-19 vaccinations for the health and safety and protection of all ...
Posted by Michael Wonder on 30 Sep 2021
Medicines industry continues to protect Australians from medicine shortages
30 September 2021 - ACCC extends approval for ongoing collaboration ...
Posted by Michael Wonder on 03 May 2021
Doubt over local mRNA plans as major companies pull out of Australia
3 May 2021 - Vaccine development experts say it will take at least $250 million plus the support of a ...
Posted by Michael Wonder on 18 Apr 2021
Cancer researcher David Thomas says more should be done attract big pharma
18 April 2021 - A Garvan Institute cancer researcher says the government needs to attract big pharmaceutical companies to Australia ...
Posted by Michael Wonder on 31 Jan 2021
Medicines Australia’s position on potential European Union restrictions and vaccines supply
30 January 2021 - Medicines Australia is concerned by the reports of proposals from Europe that could impact the global ...
Posted by Michael Wonder on 24 Sep 2020
'Pharma resistance’ to battle superbugs
24 September 2020 - A group of pharmaceutical giants, biotech companies, industry peak bodies and the CSIRO have banded together ...
Posted by Michael Wonder on 06 Dec 2019
Proposed changes to research and development tax incentive will discourage investment and undermine innovation
6 December 2019 - Medicines Australia is disappointed that proposed changes to the Research and Development Tax Incentive were tabled ...
Posted by Michael Wonder on 26 Jul 2019
Intellectual property law amends will add to business uncertainty
26 July 2019 - Medicines Australia supports efforts to strengthen Australia’s Intellectual Property arrangements to be consistent with international best ...
Posted by Michael Wonder on 20 Sep 2018
ACCC approves local merger of pharma firms Arrow and Apotex
20 September 2018 - Half of all generic prescriptions could come from one supplier after the competition watchdog approved a ...
Posted by Michael Wonder on 10 Jul 2018
Medicines Australia welcomes priority review pathway programme milestone
10 July 2018 - Last week saw the listing of Eryland (apalutamide) for the treatment men with non-metastatic (castration-resistant) prostate ...
Posted by Michael Wonder on 06 Jun 2018
Big pharma wants to invest more in Australian biotech says Greg Hunt
6 June 2018 - Big pharma is "looking at Australia as the next destination in the developed world, the emerging first-world ...